open access

Vol 50, No 3 (2012)
ORIGINAL PAPERS
Published online: 2012-10-08
Submitted: 2012-10-08
Accepted: 2012-10-08
Get Citation

Inverse relationship between TCTP/RhoA and p53/ /cyclin A/actin expression in ovarian cancer cells

Malgorzata Kloc, Neelam Tejpal, Jitinderpal Sidhu, Malathesha Ganachari, Pedro Flores-Villanueva, Nicholas B. Jennings, Anil K. Sood, Jacek Z. Kubiak, Rafik M. Ghobrial
DOI: 10.5603/FHC.2012.0049
·
Folia Histochem Cytobiol 2012;50(3):358-367.

open access

Vol 50, No 3 (2012)
ORIGINAL PAPERS
Published online: 2012-10-08
Submitted: 2012-10-08
Accepted: 2012-10-08

Abstract

The translationally controlled tumor protein (TCTP) plays a role in cell growth, cell cycle and cancer
progression. TCTP controls negatively the stability of the p53 tumor suppressor protein and interacts with the
cellular cytoskeleton. The deregulation of the actin and cytokeratin cytoskeleton is responsible for the increased
migratory activity of tumor cells and is linked with poor patient outcome. Recent studies indicate that cyclin A,
a key regulator of cell cycle, controls actin organization and negatively regulates cell motility via regulation of RhoA
expression. We studied the organization of actin and cytokeratin cytoskeleton and the expression of TCTP, p53,
cyclin A, RhoA and actin in HIO180 non-transformed ovarian epithelial cells, and OVCAR3 and SKOV3 (expressing
low level of inducible p53) ovarian epithelial cancer cells with different metastatic potential. Immunostaining
and ultrastructural analyses illustrated a dramatic difference in the organization of the cytokeratin and actin
filaments in non-transformed versus cancer cell lines. We also determined that there is an inverse relationship between
the level of TCTP/RhoA and actin/p53/cyclin A expression in ovarian cancer cell lines. This previously unidentified
negative relationship between TCTP/RhoA and actin/p53/cyclin A may suggest that this interaction is linked
with the high aggressiveness of ovarian cancers.

Abstract

The translationally controlled tumor protein (TCTP) plays a role in cell growth, cell cycle and cancer
progression. TCTP controls negatively the stability of the p53 tumor suppressor protein and interacts with the
cellular cytoskeleton. The deregulation of the actin and cytokeratin cytoskeleton is responsible for the increased
migratory activity of tumor cells and is linked with poor patient outcome. Recent studies indicate that cyclin A,
a key regulator of cell cycle, controls actin organization and negatively regulates cell motility via regulation of RhoA
expression. We studied the organization of actin and cytokeratin cytoskeleton and the expression of TCTP, p53,
cyclin A, RhoA and actin in HIO180 non-transformed ovarian epithelial cells, and OVCAR3 and SKOV3 (expressing
low level of inducible p53) ovarian epithelial cancer cells with different metastatic potential. Immunostaining
and ultrastructural analyses illustrated a dramatic difference in the organization of the cytokeratin and actin
filaments in non-transformed versus cancer cell lines. We also determined that there is an inverse relationship between
the level of TCTP/RhoA and actin/p53/cyclin A expression in ovarian cancer cell lines. This previously unidentified
negative relationship between TCTP/RhoA and actin/p53/cyclin A may suggest that this interaction is linked
with the high aggressiveness of ovarian cancers.
Get Citation
About this article
Title

Inverse relationship between TCTP/RhoA and p53/ /cyclin A/actin expression in ovarian cancer cells

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 3 (2012)

Pages

358-367

Published online

2012-10-08

DOI

10.5603/FHC.2012.0049

Bibliographic record

Folia Histochem Cytobiol 2012;50(3):358-367.

Authors

Malgorzata Kloc
Neelam Tejpal
Jitinderpal Sidhu
Malathesha Ganachari
Pedro Flores-Villanueva
Nicholas B. Jennings
Anil K. Sood
Jacek Z. Kubiak
Rafik M. Ghobrial

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl